ArticleBMC microbiology2026
Large-genome phage vB_Eco_ZCEC15 targets gastrointestinal MDR E. coli: evidence from in vitro and Caco-2 cell models.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBacterial resistance to traditional antibiotics is spreading at an alarming rate, threatening public health and various industrial applications. Phage therapy has emerged as a promising alternative for combating multidrug-resistant (MDR) bacterial infections. However, most studies have focused on in vitro interactions, often overlooking phage dynamics within human cell environments. METHODOLOGY: In this study, we characterized MDR stool-derived Escherichia coli isolates and assessed their antibiotic resistance profiles. We then isolated, characterized and evaluated the efficacy of bacteriophage vB_Eco_ZCEC15 (ΦZCEC15) against selected strains under optimized culture conditions (pH 7.3) and acidic conditions mimicking the human gastrointestinal tract. To assess host safety, we tested the impact of ΦZCEC15 on Caco-2 colon carcinoma cells. Furthermore, we explored the effect of bacterial lysis by ΦZCEC15 on Caco-2 cell viability to optimize its therapeutic applications.
resultsWhole-genome sequencing revealed a large ΦZCEC15 genome (170,313 bp) encoding 272 annotated ORFs, eight tRNAs, and multiple accessory genes. The phage exhibited remarkable stability under diverse physical stressors, including pH 3. Notably, ΦZCEC15 achieved optimal antibacterial activity at a low multiplicity of infection (MOI 0.1), efficiently reducing bacterial titers without compromising eukaryotic host cell viability. In contrast, untreated bacterial infections induced cytotoxic effects in Caco-2 cells.
conclusionThese findings highlight the potential of ΦZCEC15 as a safe and effective therapeutic agent against MDR E. coli and encourage the importance of addressing resistance mechanisms to optimize clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.